<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Primary Carnitine Deficiency - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
            --banner-bg: #fef3c7;
            --banner-border: #f59e0b;
            --banner-text: #92400e;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .notice-banner {
            background: var(--banner-bg);
            color: var(--banner-text);
            border-bottom: 1px solid var(--banner-border);
            padding: 12px 16px;
            text-align: center;
            font-size: 0.95rem;
            cursor: pointer;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-location {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-component {
            background: #f0fdf4;
            color: #166534;
        }

        .tag-complex {
            background: #faf5ff;
            color: #7e22ce;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-name-link {
            color: inherit;
            text-decoration: underline;
            text-underline-offset: 2px;
            text-decoration-thickness: 1px;
        }

        .item-name-link:hover {
            text-decoration-thickness: 2px;
        }

        .missing-disease-name {
            color: #991b1b;
            border-bottom: 1px dotted #dc2626;
        }

        .curation-gap-badge {
            display: inline-flex;
            align-items: center;
            margin-left: 8px;
            padding: 2px 8px;
            border-radius: 999px;
            font-size: 0.72rem;
            font-weight: 700;
            letter-spacing: 0.01em;
            text-transform: uppercase;
            background: #fef2f2;
            border: 1px solid #fecaca;
            color: #b91c1c;
            vertical-align: middle;
        }

        .missing-ontology-link {
            color: #b91c1c !important;
            text-decoration: underline dotted;
            text-underline-offset: 2px;
        }

        .dismech-inline-link {
            margin-left: 6px;
            font-size: 0.78rem;
            font-weight: 600;
            color: #0369a1;
            text-decoration: underline;
            text-underline-offset: 2px;
            text-decoration-thickness: 1px;
            white-space: nowrap;
        }

        .dismech-inline-link:hover {
            text-decoration-thickness: 2px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Phenotype TOC strip */
        .pheno-toc {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #e2e8f0;
            margin-bottom: 4px;
        }

        .pheno-toc-pill {
            display: inline-block;
            font-size: 0.78rem;
            padding: 3px 10px;
            border-radius: 12px;
            background: #dcfce7;
            color: #166534;
            text-decoration: none;
            cursor: pointer;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toc-pill:hover {
            background: #bbf7d0;
        }

        .pheno-toc-pill .pill-count {
            font-weight: 600;
            margin-left: 2px;
        }

        .pheno-toggle-all {
            font-size: 0.78rem;
            color: #16a34a;
            cursor: pointer;
            background: none;
            border: 1px solid #bbf7d0;
            border-radius: 6px;
            padding: 3px 10px;
            margin-left: auto;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toggle-all:hover {
            background: #f0fdf4;
        }

        /* Collapsible category groups */
        .phenotype-category-group {
            margin-bottom: 2px;
        }

        .phenotype-category-group summary {
            font-size: 0.85rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #16a34a;
            margin: 0;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #bbf7d0;
            cursor: pointer;
            list-style: none;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .phenotype-category-group summary::-webkit-details-marker {
            display: none;
        }

        .phenotype-category-group summary .chevron {
            display: inline-block;
            width: 16px;
            height: 16px;
            transition: transform 0.15s;
            flex-shrink: 0;
        }

        .phenotype-category-group[open] summary .chevron {
            transform: rotate(90deg);
        }

        .phenotype-category-group summary .cat-count {
            font-size: 0.75rem;
            font-weight: 400;
            color: #15803d;
            background: #dcfce7;
            padding: 1px 7px;
            border-radius: 8px;
        }

        /* Phenotype Contexts */
        .phenotype-contexts {
            margin-top: 10px;
        }

        .phenotype-contexts-toggle {
            font-size: 0.8rem;
            color: var(--text-muted);
            cursor: pointer;
            user-select: none;
        }

        .phenotype-contexts-toggle:hover {
            color: var(--primary);
        }

        .context-card {
            padding: 10px 14px;
            margin-top: 8px;
            border-radius: 8px;
            background: #ecfdf5;
            border: 1px solid #a7f3d0;
            font-size: 0.88rem;
        }

        .context-header {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 6px;
            margin-bottom: 6px;
        }

        .context-label {
            font-size: 0.72rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            padding: 2px 8px;
            border-radius: 4px;
        }

        .context-label-genetic {
            background: #dbeafe;
            color: #1e40af;
        }

        .context-label-sex {
            background: #fce7f3;
            color: #9d174d;
        }

        .context-label-population {
            background: #fef3c7;
            color: #92400e;
        }

        .context-label-age {
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-label-subtype {
            background: #ede9fe;
            color: #5b21b6;
        }

        .context-label-frequency {
            background: #dcfce7;
            color: #166534;
        }

        .context-gene-list {
            display: flex;
            flex-wrap: wrap;
            gap: 4px;
            margin: 4px 0;
        }

        .context-gene-tag {
            font-size: 0.78rem;
            font-weight: 600;
            padding: 1px 8px;
            border-radius: 4px;
            background: #bfdbfe;
            color: #1e3a8a;
        }

        .context-detail {
            font-size: 0.84rem;
            color: #065f46;
            line-height: 1.5;
        }

        .context-detail strong {
            color: #047857;
        }

        .context-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #bbf7d0;
            color: #14532d;
            font-weight: 600;
        }

        .context-onset {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-severity {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #fef3c7;
            color: #92400e;
        }

        .context-notes {
            font-size: 0.84rem;
            color: #065f46;
            margin-top: 4px;
            line-height: 1.5;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }
        .classification-header {
            font-size: 1rem;
            font-weight: 600;
            color: #4338ca;
            margin: 1.2rem 0 0.5rem 0;
            padding-bottom: 0.3rem;
            border-bottom: 2px solid #c7d2fe;
            text-transform: capitalize;
        }
        .subtype-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin: 0.3rem 0;
        }
        .subtype-freq-badge {
            background: #dbeafe;
            color: #1e40af;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-gene-tag {
            background: #fef3c7;
            color: #92400e;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-inheritance-tag {
            background: #ede9fe;
            color: #5b21b6;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-term-link {
            font-size: 0.8rem;
            color: #6366f1;
            text-decoration: none;
        }
        .subtype-term-link:hover { text-decoration: underline; }
        .subtype-children {
            margin: 0.4rem 0 0.2rem 1rem;
            padding: 0;
            list-style: none;
        }
        .subtype-children li {
            font-size: 0.85rem;
            color: #4338ca;
            padding: 0.1rem 0;
        }
        .subtype-children li::before {
            content: "‚Ü≥ ";
            color: #a5b4fc;
        }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    <div class="notice-banner" role="button" tabindex="0">This resource is in its pre-alpha development stage. Content is actively being curated and may be incomplete or subject to change.</div>
    

    

    
    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Primary Carnitine Deficiency</span>
        </nav>

        <header class="page-header">
            <h1>Primary Carnitine Deficiency</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Mendelian</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0008919" target="_blank">
                        MONDO:0008919
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Fatty Acid Oxidation Disorder</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Inborn Error of Metabolism</span>
                
            </div>
            
            <p style="margin-top: 16px; font-size: 1rem; line-height: 1.6; opacity: 0.95; position: relative;">
                Primary carnitine deficiency (PCD) is an autosomal recessive disorder of fatty acid oxidation caused by loss-of-function variants in SLC22A5, encoding the high-affinity sodium-dependent carnitine transporter OCTN2. Defective OCTN2 leads to impaired cellular uptake and renal tubular reabsorption of carnitine, causing systemic carnitine depletion and impaired mitochondrial long-chain fatty acid beta-oxidation. The clinical spectrum is bimodal, with acute metabolic decompensation in infancy (hypoketotic hypoglycemia, hyperammonemia, hepatic encephalopathy) and a more insidious cardiomyopathy phenotype (dilated or hypertrophic) often accompanied by skeletal myopathy. PCD is treatable with lifelong oral L-carnitine supplementation, which can reverse cardiomyopathy if started early. Estimated prevalence is approximately 1 in 20,000 in Chinese populations, with regional and ethnic variation.

            </p>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Inheritance</div>
            </div>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Pathophysiology</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">12</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#genetic">
            <div class="stat-item">
                <div class="stat-value">1</div>
                <div class="stat-label">Genes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">7</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#subtypes">
            <div class="stat-item">
                <div class="stat-value">2</div>
                <div class="stat-label">Subtypes</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
            
        </div>

        <!-- Classifications -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üè∑</div>
                <h2 class="card-title">Classifications</h2>
            </div>
            
            <div style="margin-bottom: 16px;">
                <div class="classification-category">Harrison's Chapter</div>
                <div class="tag-list">
                    
                    <span class="tag tag-classification">hereditary disease</span>
                    
                </div>
            </div>
            
            
            
            
            
            
        </div>
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        

        <!-- Subtypes -->
        
        <div class="card" id="subtypes">
            <div class="card-header">
                <div class="card-icon" style="background: #eef2ff; color: #4f46e5;">‚óÜ</div>
                <h2 class="card-title">Subtypes</h2>
                <span class="card-count">2</span>
            </div>
            
            
            
                
                
                    
                
                
            
                
                
                
            
            
                
                
                
                
                
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        
                        Infantile acute metabolic primary carnitine deficiency
                        
                        
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Early-onset subtype characterized by acute metabolic decompensation episodes with hypoketotic hypoglycemia, hyperammonemia, and encephalopathy, often precipitated by fasting or intercurrent illness.
</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38585546" target="_blank">PMID:38585546</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Carnitine deficiency can result in acute metabolic decompensation or, in a more insidious presentation, cardiomyopathy."</div>
                
                
                <div class="evidence-explanation">Supports an acute metabolic presentation subtype in PCD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
                
                
                
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        
                        Cardiac primary carnitine deficiency
                        
                        
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Cardiac-dominant subtype with dilated or hypertrophic cardiomyopathy and heart failure risk, often with more insidious progression.
</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38585546" target="_blank">PMID:38585546</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Cardiomyopathy associated with PCD often presents with life-threatening heart failure."</div>
                
                
                <div class="evidence-explanation">Supports a cardiac-predominant subtype with severe cardiomyopathy risk.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
            
        </div>
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">‚öô</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">SLC22A5/OCTN2 transporter dysfunction</div>
                
                <div class="item-desc">Loss-of-function variants in SLC22A5 impair OCTN2-mediated transmembrane carnitine transport in kidney and other tissues.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        epithelial cell of proximal tubule
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0002306" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-gene">
                        SLC22A5
                        
                    </span>
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        transmembrane transporter activity
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0022857" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        carnitine transmembrane transport
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006839" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        kidney
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0002113" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38961493" target="_blank">PMID:38961493</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Primary carnitine deficiency (PCD) is a rare autosomal recessive fatty acid oxidation disorder caused by variants in SLC22A5, with its prevalence and SLC22A5 gene mutation spectrum varying across races and regions."</div>
                
                
                <div class="evidence-explanation">Confirms autosomal recessive etiology with SLC22A5 variants across populations.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Systemic carnitine depletion</div>
                
                <div class="item-desc">Defective renal tubular reabsorption causes urinary carnitine wasting, producing low plasma free carnitine and tissue carnitine depletion. This is the proximal biochemical consequence driving downstream metabolic failure.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        epithelial cell of proximal tubule
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0002306" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        carnitine transmembrane transport
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006839" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        kidney
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0002113" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38585546" target="_blank">PMID:38585546</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Carnitine deficiency can result in acute metabolic decompensation or, in a more insidious presentation, cardiomyopathy."</div>
                
                
                <div class="evidence-explanation">Supports systemic carnitine depletion as the proximal biochemical state linked to the clinical syndrome.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Impaired mitochondrial fatty acid beta-oxidation</div>
                
                <div class="item-desc">Intracellular carnitine depletion impairs the carnitine shuttle system, reducing transfer of long-chain fatty acids into mitochondria for beta-oxidation. This causes energy failure particularly in tissues with high fatty acid oxidation demand such as heart and skeletal muscle, and drives metabolic decompensation during fasting or catabolic stress.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        cardiac muscle cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000746" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        skeletal muscle fiber
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0008002" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        fatty acid beta-oxidation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006635" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39091928" target="_blank">PMID:39091928</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"Primary Carnitine Deficiency (PCD) is a potentially life-threatening autosomal recessive monogenic disorder arising from mutations in the organic cation transporter 2 (OCTN2) gene. Dilated cardiomyopathy (DCM) is a prevalent symptom associated with this condition, and episodes of metabolic..."</div>
                
                
                <div class="evidence-explanation">Links OCTN2 mutations to cardiomyopathy and metabolic disturbance, supporting impaired fatty acid oxidation as a central mechanism.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38585546" target="_blank">PMID:38585546</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Carnitine deficiency can result in acute metabolic decompensation or, in a more insidious presentation, cardiomyopathy."</div>
                
                
                <div class="evidence-explanation">Confirms that carnitine depletion leads to both metabolic crises and cardiomyopathy.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Cardiac remodeling and fibrosis in OCTN2 deficiency</div>
                
                <div class="item-desc">Chronic carnitine depletion in cardiomyocytes suppresses contractile and calcium-handling gene programs, triggers fibroblast expansion, and activates pro-fibrotic macrophage signaling. Single-nucleus RNA-seq studies of OCTN2-deficient hearts reveal downregulation of contractile genes (MYH7, TNNI3, TNNT2, RYR2), increased fibroblast abundance, elevated GAS6-AXL signaling initiating fibrosis through EMT, and SPP1-positive macrophage-driven fibroblast activation.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        cardiac muscle cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000746" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        fibroblast
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000057" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        macrophage
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000235" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        extracellular matrix organization
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0030198" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        cardiac muscle contraction
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0060048" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        heart
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0000948" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39091928" target="_blank">PMID:39091928</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"OCTN2-deficient cardiomyocytes displayed transcriptomic alterations indicative of reduced contractility, developmental abnormalities, and fibrosis."</div>
                
                
                <div class="evidence-explanation">Directly supports cardiac remodeling with reduced contractility and fibrosis in PCD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Hepatic metabolic decompensation and encephalopathy</div>
                
                <div class="item-desc">In the liver, carnitine deficiency impairs fatty acid oxidation and ketogenesis, leading to hypoketotic hypoglycemia during fasting. Accumulation of toxic metabolites contributes to hyperammonemia and hepatic encephalopathy, particularly in the infantile presentation of PCD.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        hepatocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000182" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        ketone body biosynthetic process
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0046951" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        liver
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0002107" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40406429" target="_blank">PMID:40406429</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Carnitine acts as a vital component in facilitating the transport of long-chain fatty acids into the mitochondria, thereby enabling their oxidation for the generation of energy. Carnitine additionally assumes a crucial role in the functionality of the brain. Carnitine deficiency is associated..."</div>
                
                
                <div class="evidence-explanation">Supports carnitine&#39;s role in hepatic fatty acid oxidation and brain function, linking deficiency to encephalopathy.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38585546" target="_blank">PMID:38585546</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Carnitine deficiency can result in acute metabolic decompensation or, in a more insidious presentation, cardiomyopathy."</div>
                
                
                <div class="evidence-explanation">Confirms acute metabolic decompensation as a presentation of PCD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">‚¨°</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph LR
    Hepatic_metabolic_decompensation_and_encephalopathy[&#34;Hepatic metabolic decompensation and encephalopathy&#34;]
    SLC22A5_OCTN2_transporter_dysfunction[&#34;SLC22A5/OCTN2 transporter dysfunction&#34;]
    Cardiac_remodeling_and_fibrosis_in_OCTN2_deficiency[&#34;Cardiac remodeling and fibrosis in OCTN2 deficiency&#34;]
    Impaired_mitochondrial_fatty_acid_beta_oxidation[&#34;Impaired mitochondrial fatty acid beta-oxidation&#34;]
    Systemic_carnitine_depletion[&#34;Systemic carnitine depletion&#34;]

    SLC22A5_OCTN2_transporter_dysfunction --&gt; Systemic_carnitine_depletion
    Systemic_carnitine_depletion --&gt; Impaired_mitochondrial_fatty_acid_beta_oxidation
    Impaired_mitochondrial_fatty_acid_beta_oxidation --&gt; Cardiac_remodeling_and_fibrosis_in_OCTN2_deficiency
    Impaired_mitochondrial_fatty_acid_beta_oxidation --&gt; Hepatic_metabolic_decompensation_and_encephalopathy

    style Hepatic_metabolic_decompensation_and_encephalopathy fill:#dbeafe
    style SLC22A5_OCTN2_transporter_dysfunction fill:#dbeafe
    style Cardiac_remodeling_and_fibrosis_in_OCTN2_deficiency fill:#dbeafe
    style Impaired_mitochondrial_fatty_acid_beta_oxidation fill:#dbeafe
    style Systemic_carnitine_depletion fill:#dbeafe</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">‚óè</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">12</span>
            </div>
            
            
            <div class="pheno-toc">
                
                <a class="pheno-toc-pill" data-target="pheno-cat-1">Cardiovascular<span class="pill-count">(2)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-2">Digestive<span class="pill-count">(2)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-3">Metabolism<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-4">Musculoskeletal<span class="pill-count">(2)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-5">Nervous System<span class="pill-count">(2)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-6">Growth<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-7">Other<span class="pill-count">(2)</span></a>
                
                <button class="pheno-toggle-all" id="phenoToggleAll">Expand all</button>
            </div>
            
            
            <details class="phenotype-category-group" id="pheno-cat-1">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Cardiovascular
                    <span class="cat-count">2</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Dilated cardiomyopathy
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001644" target="_blank">
                                Dilated cardiomyopathy
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001644)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38585546" target="_blank">PMID:38585546</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Cardiomyopathy associated with PCD often presents with life-threatening heart failure."</div>
                
                
                <div class="evidence-explanation">Directly supports cardiomyopathy as a frequent life-threatening manifestation.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39091928" target="_blank">PMID:39091928</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"Dilated cardiomyopathy (DCM) is a prevalent symptom associated with this condition, and episodes of metabolic disturbance may lead to sudden death."</div>
                
                
                <div class="evidence-explanation">Confirms DCM as a prevalent feature of PCD.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Hypertrophic cardiomyopathy
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001639" target="_blank">
                                Hypertrophic cardiomyopathy
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001639)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39691889" target="_blank">PMID:39691889</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Primary carnitine deficiency may mimic hypertrophic cardiomyopathy and be mistakenly attributed to genotype-negative sarcomeric protein dysfunction in hypertrophic cardiomyopathy."</div>
                
                
                <div class="evidence-explanation">Directly supports HCM as a phenocopy presentation of PCD.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38166572" target="_blank">PMID:38166572</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Clinical evaluations, echocardiography, and cardiac magnetic resonance imaging findings revealed hypertrophic cardiomyopathy as a clinical presentation of PCD."</div>
                
                
                <div class="evidence-explanation">Confirms HCM as a clinical presentation in a confirmed PCD case.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-2">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Digestive
                    <span class="cat-count">2</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Hepatomegaly
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002240" target="_blank">
                                Hepatomegaly
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002240)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Hepatomegaly during acute metabolic decompensation is described in PCD case reports with hepatic dysfunction.</div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Hepatic steatosis
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001397" target="_blank">
                                Hepatic steatosis
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001397)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Hepatic steatosis is mechanistically plausible in severe carnitine deficiency via impaired fatty acid oxidation, but the current abstract evidence does not directly quote steatosis in PCD cohorts.</div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-3">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Metabolism
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Hypoketotic hypoglycemia
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001985" target="_blank">
                                Hypoketotic hypoglycemia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001985)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38585546" target="_blank">PMID:38585546</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Carnitine deficiency can result in acute metabolic decompensation or, in a more insidious presentation, cardiomyopathy."</div>
                
                
                <div class="evidence-explanation">Supports metabolic decompensation as a clinical presentation, which includes hypoketotic hypoglycemia.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40406429" target="_blank">PMID:40406429</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Carnitine deficiency is associated with various types of inherited disorders related to low levels of carnitine."</div>
                
                
                <div class="evidence-explanation">Supports carnitine deficiency as the underlying cause of metabolic decompensation features.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-4">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Musculoskeletal
                    <span class="cat-count">2</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Skeletal myopathy
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0003198" target="_blank">
                                Myopathy
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0003198)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38585546" target="_blank">PMID:38585546</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"This presentation also usually includes skeletal muscle myopathy."</div>
                
                
                <div class="evidence-explanation">Directly supports skeletal myopathy as a frequent accompanying feature.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Muscular hypotonia
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001252" target="_blank">
                                Hypotonia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001252)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38585546" target="_blank">PMID:38585546</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"This presentation also usually includes skeletal muscle myopathy."</div>
                
                
                <div class="evidence-explanation">Skeletal myopathy presentation is consistent with hypotonia as a feature.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-5">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Nervous System
                    <span class="cat-count">2</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Lethargy
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001254" target="_blank">
                                Lethargy
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001254)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38166572" target="_blank">PMID:38166572</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"We herein describe an 8-year-old boy with symptoms of weakness and lethargy diagnosed with PCD through clinical evaluations, lab tests, echocardiography, and cardiac magnetic resonance imaging."</div>
                
                
                <div class="evidence-explanation">Directly reports lethargy as a presenting symptom in a confirmed PCD patient. Frequency based on limited case reports.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Encephalopathy
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001298" target="_blank">
                                Encephalopathy
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001298)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40406429" target="_blank">PMID:40406429</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"A strong correlation exists between the insufficiency of carnitine and the occurrence of HE."</div>
                
                
                <div class="evidence-explanation">Supports encephalopathy risk in severe carnitine deficiency through association with hepatic encephalopathy.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-6">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Growth
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Failure to thrive
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001508" target="_blank">
                                Failure to thrive
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001508)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Failure to thrive is described in PCD case reports as a consequence of recurrent metabolic crises and energy deficiency.</div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-7">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Other
                    <span class="cat-count">2</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Hyperammonemia
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001987" target="_blank">
                                Hyperammonemia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001987)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40406429" target="_blank">PMID:40406429</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"A strong correlation exists between the insufficiency of carnitine and the occurrence of HE."</div>
                
                
                <div class="evidence-explanation">Supports the link between carnitine deficiency and hyperammonemia/encephalopathy.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38585546" target="_blank">PMID:38585546</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Carnitine deficiency can result in acute metabolic decompensation or, in a more insidious presentation, cardiomyopathy."</div>
                
                
                <div class="evidence-explanation">Metabolic decompensation in PCD includes hyperammonemia.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Cardiac arrest
                        
                        <span class="phenotype-freq">VERY_RARE</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001695" target="_blank">
                                Cardiac arrest
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001695)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39091928" target="_blank">PMID:39091928</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-MODEL_ORGANISM">Model Organism</span>
                    
                </div>
                
                <div class="evidence-snippet">"episodes of metabolic disturbance may lead to sudden death."</div>
                
                
                <div class="evidence-explanation">Directly states that metabolic disturbance episodes in PCD can lead to sudden death.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <script>
            (function() {
                // TOC pill click: expand target group and scroll to it
                document.querySelectorAll('.pheno-toc-pill').forEach(function(pill) {
                    pill.addEventListener('click', function() {
                        var target = document.getElementById(pill.dataset.target);
                        if (target) {
                            target.open = true;
                            target.scrollIntoView({behavior: 'smooth', block: 'start'});
                        }
                    });
                });
                // Expand/collapse all toggle
                var btn = document.getElementById('phenoToggleAll');
                if (btn) {
                    btn.addEventListener('click', function() {
                        var groups = document.querySelectorAll('.phenotype-category-group');
                        var anyOpen = Array.from(groups).some(function(g) { return g.open; });
                        groups.forEach(function(g) { g.open = !anyOpen; });
                        btn.textContent = anyOpen ? 'Expand all' : 'Collapse all';
                    });
                }
            })();
            </script>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card" id="genetic">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">üß¨</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    SLC22A5 (OCTN2) pathogenic variants
                    
                </div>
                
                <div class="item-meta">
                    
                    <span class="tag" style="background: #bfdbfe; color: #1e40af;">Autosomal recessive</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39201429" target="_blank">PMID:39201429</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-COMPUTATIONAL">Computational</span>
                    
                </div>
                
                <div class="evidence-snippet">"A plethora of missense variants with uncertain clinical significance are reported both in the dbSNP and the Catalogue of Somatic Mutations in Cancer (COSMIC) databases for both genes."</div>
                
                
                <div class="evidence-explanation">Confirms the large number of SLC22A5 variants and their clinical importance.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">üíä</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">7</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    L-carnitine supplementation
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Lifelong oral L-carnitine replacement is the disease-modifying cornerstone of PCD management. Standard dosing is 100-300 mg/kg/day in divided doses, titrated to plasma free carnitine levels and clinical response. Early treatment can reverse cardiomyopathy, with LVEF normalization reported within months.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38585546" target="_blank">PMID:38585546</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Early recognition of this disorder and treatment with carnitine can avoid life-threatening complications related to cardiomyopathy."</div>
                
                
                <div class="evidence-explanation">Supports the critical importance of early carnitine treatment.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Dietary management
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000088" target="_blank">
                            MAXO:0000088
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Avoidance of prolonged fasting is essential to prevent metabolic decompensation. Frequent feeding schedules and carbohydrate-rich snacks before bed help maintain energy supply and reduce dependence on fatty acid oxidation.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38585546" target="_blank">PMID:38585546</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Carnitine deficiency can result in acute metabolic decompensation or, in a more insidious presentation, cardiomyopathy."</div>
                
                
                <div class="evidence-explanation">Prevention of metabolic decompensation through dietary management is a standard approach.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Acute decompensation management
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000950" target="_blank">
                            MAXO:0000950
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Emergency supportive care during metabolic crises includes intravenous glucose infusion to reverse catabolism, correction of metabolic acidosis, treatment of hyperammonemia, and intravenous L-carnitine. Prompt intervention prevents progression to encephalopathy and organ failure.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38585546" target="_blank">PMID:38585546</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Carnitine deficiency can result in acute metabolic decompensation or, in a more insidious presentation, cardiomyopathy."</div>
                
                
                <div class="evidence-explanation">Acute metabolic decompensation requires emergency supportive management.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40406429" target="_blank">PMID:40406429</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"If a deficiency of carnitine is identified through clinical symptoms or laboratory results in patients with liver dysfunction, treatment with carnitine replacement therapy is recommended."</div>
                
                
                <div class="evidence-explanation">Supports carnitine replacement as treatment during acute episodes.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Newborn screening
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000124" target="_blank">
                            MAXO:0000124
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">NBS for PCD uses tandem mass spectrometry to measure free carnitine (C0) in dried blood spots. The condition is of high screening complexity due to pitfalls including maternal PCD, premature birth, and medication effects on C0 levels. Second-tier NGS testing can improve positive predictive value from approximately 5% to 20%.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36810318" target="_blank">PMID:36810318</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"This disease is of high complexity to screen, due to its pathophysiology and wide clinical spectrum."</div>
                
                
                <div class="evidence-explanation">Confirms the complexity and importance of NBS for PCD.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39248612" target="_blank">PMID:39248612</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"The PPV reached 20% after combining with second-tier NGS."</div>
                
                
                <div class="evidence-explanation">Demonstrates improved screening performance with NGS second-tier testing.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Cardiac management
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Standard heart failure therapy including ACE inhibitors, beta-blockers, and diuretics may be required for patients presenting with cardiomyopathy and heart failure. Cardiac monitoring with echocardiography is essential for long-term follow-up. ICD placement may be considered for arrhythmia management.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38585546" target="_blank">PMID:38585546</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Cardiomyopathy associated with PCD often presents with life-threatening heart failure."</div>
                
                
                <div class="evidence-explanation">Heart failure presentation necessitates cardiac pharmacotherapy.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Genetic counseling
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000079" target="_blank">
                            MAXO:0000079
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Genetic counseling is essential for affected families, including discussion of autosomal recessive inheritance, 25% recurrence risk for each pregnancy, carrier testing for family members, and prenatal or preimplantation genetic testing options. NBS may also detect maternal PCD through low C0 in the infant.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38961493" target="_blank">PMID:38961493</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Primary carnitine deficiency (PCD) is a rare autosomal recessive fatty acid oxidation disorder caused by variants in SLC22A5"</div>
                
                
                <div class="evidence-explanation">Autosomal recessive etiology mandates genetic counseling for affected families.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Acetyl-L-carnitine for encephalopathy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                
                <div class="item-desc">Administration of acetyl-L-carnitine in patients with hepatic encephalopathy associated with carnitine deficiency can improve mental and psychological conditions, representing an adjunctive therapeutic approach.
</div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40406429" target="_blank">PMID:40406429</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"the administration of acetyl-L-carnitine in patients with HE can improve their mental and psychological conditions."</div>
                
                
                <div class="evidence-explanation">Directly supports acetyl-L-carnitine as treatment for carnitine-associated encephalopathy.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üî¨</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">6</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Free carnitine (C0)
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(DECREASED)</span>
                    
                </div>
                
                <div class="item-desc">Context: Markedly reduced plasma free carnitine (C0) is the primary diagnostic biomarker for PCD. It is the first-tier newborn screening analyte measured by tandem mass spectrometry in dried blood spots. In one newborn-screening cohort, infants with C0 levels below 8.5 Œºmol/L were selected for second-tier genetic testing.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39248612" target="_blank">PMID:39248612</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Newborns with free carnitine (C0) levels below 8.5 Œºmol/L were selected for second-tier genetic testing."</div>
                
                
                <div class="evidence-explanation">Directly supports low C0 as the NBS trigger biomarker threshold in PCD screening workflows.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Urinary carnitine
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(INCREASED)</span>
                    
                </div>
                
                <div class="item-desc">Context: Elevated urinary carnitine excretion (carnitine wasting) results from defective OCTN2-mediated renal tubular reabsorption and is a hallmark of PCD. Fractional excretion of carnitine is markedly increased.
</div>
                
                
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Acylcarnitines
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(DECREASED)</span>
                    
                </div>
                
                <div class="item-desc">Context: Total and individual acylcarnitine species are generally reduced in PCD due to the low substrate (carnitine) availability. Acylcarnitine profiles may help differentiate PCD from secondary carnitine deficiency.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39201429" target="_blank">PMID:39201429</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-COMPUTATIONAL">Computational</span>
                    
                </div>
                
                <div class="evidence-snippet">"Due to their involvement in human pathologies, such as inflammatory-based diseases (OCTN1/2), systemic primary carnitine deficiency (OCTN2), and drug disposition, it would be interesting to predict the impact of variants on human health from the perspective of precision medicine."</div>
                
                
                <div class="evidence-explanation">Confirms OCTN2 involvement in carnitine and carnitine conjugate handling.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Ammonia
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(INCREASED)</span>
                    
                </div>
                
                <div class="item-desc">Context: Hyperammonemia occurs during acute metabolic decompensation episodes and contributes to encephalopathy. Elevated ammonia results from secondary impairment of urea cycle function.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40406429" target="_blank">PMID:40406429</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"A strong correlation exists between the insufficiency of carnitine and the occurrence of HE."</div>
                
                
                <div class="evidence-explanation">Links carnitine deficiency to hyperammonemia and hepatic encephalopathy.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Blood glucose
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(DECREASED)</span>
                    
                </div>
                
                <div class="item-desc">Context: Hypoketotic hypoglycemia occurs during fasting or metabolic stress due to impaired fatty acid oxidation and inadequate alternative energy substrate generation.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38585546" target="_blank">PMID:38585546</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"Carnitine deficiency can result in acute metabolic decompensation or, in a more insidious presentation, cardiomyopathy."</div>
                
                
                <div class="evidence-explanation">Acute metabolic decompensation in PCD includes hypoglycemia.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Creatine kinase
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(INCREASED)</span>
                    
                </div>
                
                <div class="item-desc">Context: Elevated creatine kinase may be seen in patients with skeletal myopathy or during acute episodes, reflecting muscle damage from energy failure.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38585546" target="_blank">PMID:38585546</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                    <span class="evidence-source source-HUMAN_CLINICAL">Human Clinical</span>
                    
                </div>
                
                <div class="evidence-snippet">"This presentation also usually includes skeletal muscle myopathy."</div>
                
                
                <div class="evidence-explanation">Skeletal myopathy in PCD is consistent with CK elevation.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Primary Carnitine Deficiency
category: Mendelian
creation_date: &#39;2025-06-12T20:16:27Z&#39;
updated_date: &#39;2026-02-28T02:23:00Z&#39;
synonyms:
- Carnitine uptake defect
- CUD
- Carnitine transporter deficiency
- OCTN2 deficiency
- CDSP
- Systemic primary carnitine deficiency
description: &#39;Primary carnitine deficiency (PCD) is an autosomal recessive disorder of fatty acid oxidation caused by loss-of-function
  variants in SLC22A5, encoding the high-affinity sodium-dependent carnitine transporter OCTN2. Defective OCTN2 leads to impaired
  cellular uptake and renal tubular reabsorption of carnitine, causing systemic carnitine depletion and impaired mitochondrial
  long-chain fatty acid beta-oxidation. The clinical spectrum is bimodal, with acute metabolic decompensation in infancy (hypoketotic
  hypoglycemia, hyperammonemia, hepatic encephalopathy) and a more insidious cardiomyopathy phenotype (dilated or hypertrophic)
  often accompanied by skeletal myopathy. PCD is treatable with lifelong oral L-carnitine supplementation, which can reverse
  cardiomyopathy if started early. Estimated prevalence is approximately 1 in 20,000 in Chinese populations, with regional
  and ethnic variation.

  &#39;
disease_term:
  preferred_term: systemic primary carnitine deficiency disease
  term:
    id: MONDO:0008919
    label: systemic primary carnitine deficiency disease
classifications:
  harrisons_chapter:
  - classification_value: hereditary disease
parents:
- Fatty Acid Oxidation Disorder
- Inborn Error of Metabolism
has_subtypes:
- name: Infantile acute metabolic primary carnitine deficiency
  description: &#39;Early-onset subtype characterized by acute metabolic decompensation episodes with hypoketotic hypoglycemia,
    hyperammonemia, and encephalopathy, often precipitated by fasting or intercurrent illness.

    &#39;
  evidence:
  - reference: PMID:38585546
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Carnitine deficiency can result in acute metabolic decompensation or, in a more insidious presentation, cardiomyopathy.
    explanation: Supports an acute metabolic presentation subtype in PCD.
- name: Cardiac primary carnitine deficiency
  description: &#39;Cardiac-dominant subtype with dilated or hypertrophic cardiomyopathy and heart failure risk, often with more
    insidious progression.

    &#39;
  evidence:
  - reference: PMID:38585546
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Cardiomyopathy associated with PCD often presents with life-threatening heart failure.
    explanation: Supports a cardiac-predominant subtype with severe cardiomyopathy risk.
prevalence:
- notes: Meta-analysis of Chinese NBS data estimated prevalence of 1/20,000, with higher incidence in southern China (0.07
    per mille) than northern China (0.02 per mille). China Neonatal Genomes Project estimated prevalence of approximately
    1:17,456. Prevalence varies by ethnicity and region. In Hong Kong expanded NBS, carnitine uptake defect was the most common
    IMD identified (9 of 47 total IMD cases).
progression:
- notes: Disease progression proceeds from inherited biallelic SLC22A5 variants through systemic carnitine depletion, impaired
    fatty acid oxidation, and energy failure. In the acute metabolic form, fasting or illness precipitates hypoketotic hypoglycemia,
    hyperammonemia, and encephalopathy. In the cardiac form, chronic energy deficit leads to cardiomyocyte contractile dysfunction,
    fibrosis via GAS6/AXL and SPP1-driven macrophage-fibroblast signaling, and progressive cardiomyopathy with arrhythmia
    risk and possible sudden death. Discontinuation of carnitine supplementation can precipitate fatal outcomes.
pathophysiology:
- name: SLC22A5/OCTN2 transporter dysfunction
  description: &#39;Loss-of-function variants in SLC22A5 impair OCTN2-mediated transmembrane carnitine transport in kidney and
    other tissues.

    &#39;
  genes:
  - preferred_term: SLC22A5
  biological_processes:
  - preferred_term: transmembrane transporter activity
    term:
      id: GO:0022857
      label: transmembrane transporter activity
  - preferred_term: carnitine transmembrane transport
    term:
      id: GO:0006839
      label: carnitine transmembrane transport
  cell_types:
  - preferred_term: epithelial cell of proximal tubule
    term:
      id: CL:0002306
      label: epithelial cell of proximal tubule
  locations:
  - preferred_term: kidney
    term:
      id: UBERON:0002113
      label: kidney
  evidence:
  - reference: PMID:38961493
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Primary carnitine deficiency (PCD) is a rare autosomal recessive fatty acid oxidation disorder caused by variants
      in SLC22A5, with its prevalence and SLC22A5 gene mutation spectrum varying across races and regions.
    explanation: Confirms autosomal recessive etiology with SLC22A5 variants across populations.
  downstream:
  - target: Systemic carnitine depletion
    description: Defective transport and renal reabsorption cause urinary carnitine wasting and low plasma/tissue carnitine.
- name: Systemic carnitine depletion
  description: &#39;Defective renal tubular reabsorption causes urinary carnitine wasting, producing low plasma free carnitine
    and tissue carnitine depletion. This is the proximal biochemical consequence driving downstream metabolic failure.

    &#39;
  biological_processes:
  - preferred_term: carnitine transmembrane transport
    term:
      id: GO:0006839
      label: carnitine transmembrane transport
  cell_types:
  - preferred_term: epithelial cell of proximal tubule
    term:
      id: CL:0002306
      label: epithelial cell of proximal tubule
  locations:
  - preferred_term: kidney
    term:
      id: UBERON:0002113
      label: kidney
  evidence:
  - reference: PMID:38585546
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: Carnitine deficiency can result in acute metabolic decompensation or, in a more insidious presentation, cardiomyopathy.
    explanation: Supports systemic carnitine depletion as the proximal biochemical state linked to the clinical syndrome.
  downstream:
  - target: Impaired mitochondrial fatty acid beta-oxidation
    description: Low intracellular carnitine limits mitochondrial import of long-chain fatty acids for beta-oxidation.
- name: Impaired mitochondrial fatty acid beta-oxidation
  description: &#39;Intracellular carnitine depletion impairs the carnitine shuttle system, reducing transfer of long-chain fatty
    acids into mitochondria for beta-oxidation. This causes energy failure particularly in tissues with high fatty acid oxidation
    demand such as heart and skeletal muscle, and drives metabolic decompensation during fasting or catabolic stress.

    &#39;
  biological_processes:
  - preferred_term: fatty acid beta-oxidation
    term:
      id: GO:0006635
      label: fatty acid beta-oxidation
  cell_types:
  - preferred_term: cardiac muscle cell
    term:
      id: CL:0000746
      label: cardiac muscle cell
  - preferred_term: skeletal muscle fiber
    term:
      id: CL:0008002
      label: skeletal muscle fiber
  evidence:
  - reference: PMID:39091928
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Primary Carnitine Deficiency (PCD) is a potentially life-threatening autosomal recessive monogenic disorder arising
      from mutations in the organic cation transporter 2 (OCTN2) gene. Dilated cardiomyopathy (DCM) is a prevalent symptom
      associated with this condition, and episodes of metabolic disturbance may lead to sudden death.
    explanation: Links OCTN2 mutations to cardiomyopathy and metabolic disturbance, supporting impaired fatty acid oxidation
      as a central mechanism.
  - reference: PMID:38585546
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Carnitine deficiency can result in acute metabolic decompensation or, in a more insidious presentation, cardiomyopathy.
    explanation: Confirms that carnitine depletion leads to both metabolic crises and cardiomyopathy.
  downstream:
  - target: Cardiac remodeling and fibrosis in OCTN2 deficiency
  - target: Hepatic metabolic decompensation and encephalopathy
- name: Cardiac remodeling and fibrosis in OCTN2 deficiency
  description: &#39;Chronic carnitine depletion in cardiomyocytes suppresses contractile and calcium-handling gene programs, triggers
    fibroblast expansion, and activates pro-fibrotic macrophage signaling. Single-nucleus RNA-seq studies of OCTN2-deficient
    hearts reveal downregulation of contractile genes (MYH7, TNNI3, TNNT2, RYR2), increased fibroblast abundance, elevated
    GAS6-AXL signaling initiating fibrosis through EMT, and SPP1-positive macrophage-driven fibroblast activation.

    &#39;
  biological_processes:
  - preferred_term: extracellular matrix organization
    term:
      id: GO:0030198
      label: extracellular matrix organization
  - preferred_term: cardiac muscle contraction
    term:
      id: GO:0060048
      label: cardiac muscle contraction
  cell_types:
  - preferred_term: cardiac muscle cell
    term:
      id: CL:0000746
      label: cardiac muscle cell
  - preferred_term: fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  - preferred_term: macrophage
    term:
      id: CL:0000235
      label: macrophage
  locations:
  - preferred_term: heart
    term:
      id: UBERON:0000948
      label: heart
  evidence:
  - reference: PMID:39091928
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: OCTN2-deficient cardiomyocytes displayed transcriptomic alterations indicative of reduced contractility, developmental
      abnormalities, and fibrosis.
    explanation: Directly supports cardiac remodeling with reduced contractility and fibrosis in PCD.
- name: Hepatic metabolic decompensation and encephalopathy
  description: &#39;In the liver, carnitine deficiency impairs fatty acid oxidation and ketogenesis, leading to hypoketotic hypoglycemia
    during fasting. Accumulation of toxic metabolites contributes to hyperammonemia and hepatic encephalopathy, particularly
    in the infantile presentation of PCD.

    &#39;
  biological_processes:
  - preferred_term: ketone body biosynthetic process
    term:
      id: GO:0046951
      label: ketone body biosynthetic process
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  evidence:
  - reference: PMID:40406429
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Carnitine acts as a vital component in facilitating the transport of long-chain fatty acids into the mitochondria,
      thereby enabling their oxidation for the generation of energy. Carnitine additionally assumes a crucial role in the
      functionality of the brain. Carnitine deficiency is associated with various types of inherited disorders related to
      low levels of carnitine.
    explanation: Supports carnitine&#39;s role in hepatic fatty acid oxidation and brain function, linking deficiency to encephalopathy.
  - reference: PMID:38585546
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Carnitine deficiency can result in acute metabolic decompensation or, in a more insidious presentation, cardiomyopathy.
    explanation: Confirms acute metabolic decompensation as a presentation of PCD.
phenotypes:
- name: Dilated cardiomyopathy
  frequency: FREQUENT
  description: &#39;Dilated cardiomyopathy is the most common cardiac manifestation of PCD, presenting with reduced left ventricular
    ejection fraction and heart failure. It is often the presenting feature and can be reversed with L-carnitine supplementation.

    &#39;
  phenotype_term:
    preferred_term: Dilated cardiomyopathy
    term:
      id: HP:0001644
      label: Dilated cardiomyopathy
  evidence:
  - reference: PMID:38585546
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Cardiomyopathy associated with PCD often presents with life-threatening heart failure.
    explanation: Directly supports cardiomyopathy as a frequent life-threatening manifestation.
  - reference: PMID:39091928
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Dilated cardiomyopathy (DCM) is a prevalent symptom associated with this condition, and episodes of metabolic
      disturbance may lead to sudden death.
    explanation: Confirms DCM as a prevalent feature of PCD.
- name: Hypertrophic cardiomyopathy
  frequency: OCCASIONAL
  description: &#39;PCD can mimic hypertrophic cardiomyopathy and may be mistakenly attributed to sarcomeric protein dysfunction.
    Recognition of this phenocopy is important for appropriate management.

    &#39;
  phenotype_term:
    preferred_term: Hypertrophic cardiomyopathy
    term:
      id: HP:0001639
      label: Hypertrophic cardiomyopathy
  evidence:
  - reference: PMID:39691889
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Primary carnitine deficiency may mimic hypertrophic cardiomyopathy and be mistakenly attributed to genotype-negative
      sarcomeric protein dysfunction in hypertrophic cardiomyopathy.
    explanation: Directly supports HCM as a phenocopy presentation of PCD.
  - reference: PMID:38166572
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Clinical evaluations, echocardiography, and cardiac magnetic resonance imaging findings revealed hypertrophic
      cardiomyopathy as a clinical presentation of PCD.
    explanation: Confirms HCM as a clinical presentation in a confirmed PCD case.
- name: Hypoketotic hypoglycemia
  frequency: FREQUENT
  description: &#39;Fasting intolerance with impaired ketogenesis and hypoglycemia is a hallmark of acute metabolic decompensation
    in PCD, especially in infants during intercurrent illness.

    &#39;
  phenotype_term:
    preferred_term: Hypoketotic hypoglycemia
    term:
      id: HP:0001985
      label: Hypoketotic hypoglycemia
  evidence:
  - reference: PMID:38585546
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Carnitine deficiency can result in acute metabolic decompensation or, in a more insidious presentation, cardiomyopathy.
    explanation: Supports metabolic decompensation as a clinical presentation, which includes hypoketotic hypoglycemia.
  - reference: PMID:40406429
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Carnitine deficiency is associated with various types of inherited disorders related to low levels of carnitine.
    explanation: Supports carnitine deficiency as the underlying cause of metabolic decompensation features.
- name: Hyperammonemia
  frequency: FREQUENT
  description: &#39;Secondary hyperammonemia occurs during acute metabolic decompensation, contributing to encephalopathy. The
    mechanism involves impaired urea cycle function secondary to metabolic disruption.

    &#39;
  phenotype_term:
    preferred_term: Hyperammonemia
    term:
      id: HP:0001987
      label: Hyperammonemia
  evidence:
  - reference: PMID:40406429
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: A strong correlation exists between the insufficiency of carnitine and the occurrence of HE.
    explanation: Supports the link between carnitine deficiency and hyperammonemia/encephalopathy.
  - reference: PMID:38585546
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Carnitine deficiency can result in acute metabolic decompensation or, in a more insidious presentation, cardiomyopathy.
    explanation: Metabolic decompensation in PCD includes hyperammonemia.
- name: Skeletal myopathy
  frequency: FREQUENT
  description: &#39;Progressive skeletal muscle weakness and hypotonia result from energy deficiency in oxidative muscle fibers.
    Myopathy may accompany the cardiomyopathy phenotype.

    &#39;
  phenotype_term:
    preferred_term: Myopathy
    term:
      id: HP:0003198
      label: Myopathy
  evidence:
  - reference: PMID:38585546
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This presentation also usually includes skeletal muscle myopathy.
    explanation: Directly supports skeletal myopathy as a frequent accompanying feature.
- name: Muscular hypotonia
  frequency: FREQUENT
  description: &#39;Hypotonia is a common neuromuscular finding in PCD, related to impaired energy metabolism in skeletal muscle.

    &#39;
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:38585546
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This presentation also usually includes skeletal muscle myopathy.
    explanation: Skeletal myopathy presentation is consistent with hypotonia as a feature.
- name: Hepatomegaly
  frequency: OCCASIONAL
  description: &#39;Liver enlargement may occur during acute metabolic decompensation episodes with hepatic dysfunction.

    &#39;
  phenotype_term:
    preferred_term: Hepatomegaly
    term:
      id: HP:0002240
      label: Hepatomegaly
  notes: Hepatomegaly during acute metabolic decompensation is described in PCD case reports with hepatic dysfunction.
- name: Lethargy
  frequency: OCCASIONAL
  description: &#39;Decreased alertness and lethargy occur during acute metabolic decompensation and may progress to encephalopathy.

    &#39;
  phenotype_term:
    preferred_term: Lethargy
    term:
      id: HP:0001254
      label: Lethargy
  evidence:
  - reference: PMID:38166572
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We herein describe an 8-year-old boy with symptoms of weakness and lethargy diagnosed with PCD through clinical
      evaluations, lab tests, echocardiography, and cardiac magnetic resonance imaging.
    explanation: Directly reports lethargy as a presenting symptom in a confirmed PCD patient. Frequency based on limited case reports.
- name: Cardiac arrest
  frequency: VERY_RARE
  description: &#39;Sudden cardiac death or arrest can occur in untreated PCD or with discontinuation of L-carnitine supplementation.
    Arrhythmias secondary to cardiomyopathy contribute to this risk.

    &#39;
  phenotype_term:
    preferred_term: Cardiac arrest
    term:
      id: HP:0001695
      label: Cardiac arrest
  evidence:
  - reference: PMID:39091928
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: episodes of metabolic disturbance may lead to sudden death.
    explanation: Directly states that metabolic disturbance episodes in PCD can lead to sudden death.
- name: Encephalopathy
  frequency: OCCASIONAL
  description: &#39;Metabolic encephalopathy occurs during acute decompensation episodes, presenting with altered consciousness
    ranging from excessive sleepiness to coma.

    &#39;
  phenotype_term:
    preferred_term: Encephalopathy
    term:
      id: HP:0001298
      label: Encephalopathy
  evidence:
  - reference: PMID:40406429
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: A strong correlation exists between the insufficiency of carnitine and the occurrence of HE.
    explanation: Supports encephalopathy risk in severe carnitine deficiency through association with hepatic encephalopathy.
- name: Failure to thrive
  frequency: OCCASIONAL
  description: &#39;Poor growth may occur in untreated or late-diagnosed PCD due to recurrent metabolic stress and feeding difficulties.

    &#39;
  phenotype_term:
    preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  notes: Failure to thrive is described in PCD case reports as a consequence of recurrent metabolic crises and energy deficiency.
- name: Hepatic steatosis
  frequency: OCCASIONAL
  description: &#39;Fatty liver may develop due to impaired hepatic fatty acid oxidation and lipid accumulation secondary to carnitine
    deficiency.

    &#39;
  phenotype_term:
    preferred_term: Hepatic steatosis
    term:
      id: HP:0001397
      label: Hepatic steatosis
  notes: Hepatic steatosis is mechanistically plausible in severe carnitine deficiency via impaired fatty acid oxidation, but the current abstract evidence does not directly quote steatosis in PCD cohorts.
biochemical:
- name: Free carnitine (C0)
  presence: DECREASED
  context: &#39;Markedly reduced plasma free carnitine (C0) is the primary diagnostic biomarker for PCD. It is the first-tier
    newborn screening analyte measured by tandem mass spectrometry in dried blood spots. In one newborn-screening cohort, infants
    with C0 levels below 8.5 Œºmol/L were selected for second-tier genetic testing.

    &#39;
  evidence:
  - reference: PMID:39248612
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Newborns with free carnitine (C0) levels below 8.5 Œºmol/L were selected for second-tier genetic testing.
    explanation: Directly supports low C0 as the NBS trigger biomarker threshold in PCD screening workflows.
- name: Urinary carnitine
  presence: INCREASED
  context: &#39;Elevated urinary carnitine excretion (carnitine wasting) results from defective OCTN2-mediated renal tubular reabsorption
    and is a hallmark of PCD. Fractional excretion of carnitine is markedly increased.

    &#39;
- name: Acylcarnitines
  presence: DECREASED
  context: &#39;Total and individual acylcarnitine species are generally reduced in PCD due to the low substrate (carnitine) availability.
    Acylcarnitine profiles may help differentiate PCD from secondary carnitine deficiency.

    &#39;
  evidence:
  - reference: PMID:39201429
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: Due to their involvement in human pathologies, such as inflammatory-based diseases (OCTN1/2), systemic primary
      carnitine deficiency (OCTN2), and drug disposition, it would be interesting to predict the impact of variants on human
      health from the perspective of precision medicine.
    explanation: Confirms OCTN2 involvement in carnitine and carnitine conjugate handling.
- name: Ammonia
  presence: INCREASED
  context: &#39;Hyperammonemia occurs during acute metabolic decompensation episodes and contributes to encephalopathy. Elevated
    ammonia results from secondary impairment of urea cycle function.

    &#39;
  evidence:
  - reference: PMID:40406429
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: A strong correlation exists between the insufficiency of carnitine and the occurrence of HE.
    explanation: Links carnitine deficiency to hyperammonemia and hepatic encephalopathy.
- name: Blood glucose
  presence: DECREASED
  context: &#39;Hypoketotic hypoglycemia occurs during fasting or metabolic stress due to impaired fatty acid oxidation and inadequate
    alternative energy substrate generation.

    &#39;
  evidence:
  - reference: PMID:38585546
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Carnitine deficiency can result in acute metabolic decompensation or, in a more insidious presentation, cardiomyopathy.
    explanation: Acute metabolic decompensation in PCD includes hypoglycemia.
- name: Creatine kinase
  presence: INCREASED
  context: &#39;Elevated creatine kinase may be seen in patients with skeletal myopathy or during acute episodes, reflecting muscle
    damage from energy failure.

    &#39;
  evidence:
  - reference: PMID:38585546
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This presentation also usually includes skeletal muscle myopathy.
    explanation: Skeletal myopathy in PCD is consistent with CK elevation.
genetic:
- name: SLC22A5 (OCTN2) pathogenic variants
  inheritance:
  - name: Autosomal recessive
    evidence:
    - reference: PMID:38961493
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Primary carnitine deficiency (PCD) is a rare autosomal recessive fatty acid oxidation disorder caused by variants
        in SLC22A5
      explanation: Directly confirms autosomal recessive inheritance.
  variants:
  - name: SLC22A5 - c.1400C&gt;G (p.Ser467Cys)
    description: &#39;The most common pathogenic variant in Chinese PCD patients, accounting for approximately 45% of alleles.
      Regional variation exists with lower frequency in southern China.

      &#39;
  - name: SLC22A5 - c.51C&gt;G (p.Phe17Leu)
    description: &#39;Second most common variant in Chinese PCD, accounting for approximately 26% of alleles.

      &#39;
  - name: SLC22A5 - c.760C&gt;T (p.Arg254*)
    description: &#39;Nonsense variant accounting for approximately 14% of alleles in Chinese PCD. Homozygous c.760C&gt;T carriers
      are more likely to present with cardiomyopathy.

      &#39;
    evidence:
    - reference: PMID:38125748
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: patients carrying homozygous c.760C&gt;T and c.844C&gt;T were more likely to present cardiomyopathy, whereas those
        carrying homozygous c.1400C&gt;G were more likely to be asymptomatic
      explanation: Establishes genotype-phenotype correlation for c.760C&gt;T with cardiomyopathy.
    - reference: PMID:39248612
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: the three most common variants were c.760C&gt;T (p.Arg254*), c.51C&gt;G (p.Phe17Leu), and c.1400C&gt;G (p.Ser467Cys).
      explanation: Confirms c.760C&gt;T as a common PCD variant.
  - name: SLC22A5 - c.821G&gt;A (p.Trp274Ter)
    description: &#39;Novel nonsense variant identified in an Iranian family, associated with hypertrophic cardiomyopathy. Docking
      analysis demonstrated reduced carnitine binding affinity.

      &#39;
    evidence:
    - reference: PMID:38166572
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: &#39;Whole-exome sequencing identified a new homozygous variant, SLC22A5 (NM_003060.4), c.821G &gt; A: p.Trp274Ter,
        associated with carnitine transport.&#39;
      explanation: Reports the novel pathogenic variant with functional impact on OCTN2.
  features: &#39;Biallelic pathogenic variants in SLC22A5 abolish or severely reduce OCTN2-mediated carnitine transport. A functional
    survey of 150 OCTN2 missense variants found 71% had decreased transport activity, with 37 variants showing less than 20%
    of wild-type activity. Loss-of-function variants frequently map to transmembrane domains or cause intracellular retention
    of the transporter. An alternatively spliced OCTN2-VT isoform is retained in the endoplasmic reticulum and is inactive
    for carnitine transport. Genotype-phenotype correlations exist, with homozygous c.760C&gt;T and c.844C&gt;T more likely to cause
    cardiomyopathy, while homozygous c.1400C&gt;G tends toward asymptomatic presentation.

    &#39;
  evidence:
  - reference: PMID:39201429
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: A plethora of missense variants with uncertain clinical significance are reported both in the dbSNP and the Catalogue
      of Somatic Mutations in Cancer (COSMIC) databases for both genes.
    explanation: Confirms the large number of SLC22A5 variants and their clinical importance.
treatments:
- name: L-carnitine supplementation
  description: &#39;Lifelong oral L-carnitine replacement is the disease-modifying cornerstone of PCD management. Standard dosing
    is 100-300 mg/kg/day in divided doses, titrated to plasma free carnitine levels and clinical response. Early treatment
    can reverse cardiomyopathy, with LVEF normalization reported within months.

    &#39;
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:38585546
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Early recognition of this disorder and treatment with carnitine can avoid life-threatening complications related
      to cardiomyopathy.
    explanation: Supports the critical importance of early carnitine treatment.
- name: Dietary management
  description: &#39;Avoidance of prolonged fasting is essential to prevent metabolic decompensation. Frequent feeding schedules
    and carbohydrate-rich snacks before bed help maintain energy supply and reduce dependence on fatty acid oxidation.

    &#39;
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
  evidence:
  - reference: PMID:38585546
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Carnitine deficiency can result in acute metabolic decompensation or, in a more insidious presentation, cardiomyopathy.
    explanation: Prevention of metabolic decompensation through dietary management is a standard approach.
- name: Acute decompensation management
  description: &#39;Emergency supportive care during metabolic crises includes intravenous glucose infusion to reverse catabolism,
    correction of metabolic acidosis, treatment of hyperammonemia, and intravenous L-carnitine. Prompt intervention prevents
    progression to encephalopathy and organ failure.

    &#39;
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:38585546
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Carnitine deficiency can result in acute metabolic decompensation or, in a more insidious presentation, cardiomyopathy.
    explanation: Acute metabolic decompensation requires emergency supportive management.
  - reference: PMID:40406429
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: If a deficiency of carnitine is identified through clinical symptoms or laboratory results in patients with liver
      dysfunction, treatment with carnitine replacement therapy is recommended.
    explanation: Supports carnitine replacement as treatment during acute episodes.
- name: Newborn screening
  description: &#39;NBS for PCD uses tandem mass spectrometry to measure free carnitine (C0) in dried blood spots. The condition
    is of high screening complexity due to pitfalls including maternal PCD, premature birth, and medication effects on C0
    levels. Second-tier NGS testing can improve positive predictive value from approximately 5% to 20%.

    &#39;
  treatment_term:
    preferred_term: disease screening
    term:
      id: MAXO:0000124
      label: disease screening
  evidence:
  - reference: PMID:36810318
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: This disease is of high complexity to screen, due to its pathophysiology and wide clinical spectrum.
    explanation: Confirms the complexity and importance of NBS for PCD.
  - reference: PMID:39248612
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The PPV reached 20% after combining with second-tier NGS.
    explanation: Demonstrates improved screening performance with NGS second-tier testing.
- name: Cardiac management
  description: &#39;Standard heart failure therapy including ACE inhibitors, beta-blockers, and diuretics may be required for
    patients presenting with cardiomyopathy and heart failure. Cardiac monitoring with echocardiography is essential for long-term
    follow-up. ICD placement may be considered for arrhythmia management.

    &#39;
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:38585546
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Cardiomyopathy associated with PCD often presents with life-threatening heart failure.
    explanation: Heart failure presentation necessitates cardiac pharmacotherapy.
- name: Genetic counseling
  description: &#39;Genetic counseling is essential for affected families, including discussion of autosomal recessive inheritance,
    25% recurrence risk for each pregnancy, carrier testing for family members, and prenatal or preimplantation genetic testing
    options. NBS may also detect maternal PCD through low C0 in the infant.

    &#39;
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
  evidence:
  - reference: PMID:38961493
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Primary carnitine deficiency (PCD) is a rare autosomal recessive fatty acid oxidation disorder caused by variants
      in SLC22A5
    explanation: Autosomal recessive etiology mandates genetic counseling for affected families.
- name: Acetyl-L-carnitine for encephalopathy
  description: &#39;Administration of acetyl-L-carnitine in patients with hepatic encephalopathy associated with carnitine deficiency
    can improve mental and psychological conditions, representing an adjunctive therapeutic approach.

    &#39;
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
  evidence:
  - reference: PMID:40406429
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: the administration of acetyl-L-carnitine in patients with HE can improve their mental and psychological conditions.
    explanation: Directly supports acetyl-L-carnitine as treatment for carnitine-associated encephalopathy.
notes: &#39;PCD is considered one of the most treatable inborn errors of metabolism, with cardiomyopathy often fully reversible
  if diagnosed and treated early. However, discontinuation of L-carnitine supplementation can be fatal, with reports of sudden
  death when supplementation was stopped. NBS programs are expanding worldwide but face challenges with false positives due
  to maternal PCD, premature birth, and medication effects. Side effects of high-dose carnitine include diarrhea and fishy
  body odor (trimethylamine). The 2024 single-nucleus RNA-seq study of OCTN2-deficient hearts provides new mechanistic insights
  into cardiomyopathy progression through fibrosis pathways.

  &#39;
references: []
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Primary_Carnitine_Deficiency.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
    <script>
        (function() {
            const banner = document.querySelector('.notice-banner');
            if (!banner) return;
            const dismiss = () => banner.remove();
            banner.addEventListener('click', dismiss);
            banner.addEventListener('keydown', (event) => {
                if (event.key === 'Enter' || event.key === ' ') {
                    event.preventDefault();
                    dismiss();
                }
            });
        })();
    </script>
</body>
</html>